RSV604 (5 days) inhibits the growth of four laboratory strains of RSV (RSS, Long, A2 and B), with EC 50 s ranging from 0.5 to 0.9 μM in plaque reduction assay.
It (6 days) inhibits RSV-induced HEp-2 cell death, with an EC 50 of 0.86 μM.
Also RSV604 (3 days) reduces viral antigen synthesis in RSV-infected HEp-2 cells, with an EC 50 of 1.7 μM.
RSV604 (1-20 μM; 7 days) dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells, with no gross cytotoxicity, leakage of basolateral fluid to the apical surface, or alteration of cilium beat frequency.
